Google NewsDimerix (ASX: DXB) Explodes Higher as Biotech Traders Chase Momentum - Kalkine
Dimerix (ASX: DXB) Explodes Higher as Biotech Traders Chase Momentum Kalkine
DIMERIX LTD ORDINARY (DXB) News
Latest articles and price-sensitive announcements with AI sentiment classification.
StockheadDimerix inks Asian licensing deal worth up to $480 million for kidney disease drug
In a deal worth up to circa $480 million, Dimerix has signed an exclusive Asian licensing agreement for its rare ... Read More The post Dimerix inks Asian licensing deal worth up to $480 million for kidney disease drug appeared first on Stockhead.
Dimerix (ASX:DXB) Shares Rally After Unlocking New Commercial Opportunity for DMX-200 - Kalkine
Dimerix (ASX:DXB) Shares Rally After Unlocking New Commercial Opportunity for DMX-200 Kalkine
ASXDimerix Licenses DMX200 to Everest for China and Asia Region
other announcement
Dimerix Quarterly Activities Report and Appendix 4C
other announcement
KalkineWhy Is (ASX:DXB) Dimerix Advancing Its Phase 3 Strategy?
Highlights Phase 3 pathway gains stronger clarity Trial design aligned with regulators Program momentum remains steady Dimerix continues to refine its late-stage kidney disease program, strengthening clinical confidence and aligning with regulatory expectations while progressing toward a decisive trial outcome. The biotech landscape often shifts on subtle developments rather than headline-grabbing breakthroughs. One such example is Dimerix Ltd (ASX:DXB), which has recently taken a measu...
Shares In Dimerix (ASX:DXB) Fell 35% Today; Not About The Data, But About the Timing - Stocks Down Under
Shares In Dimerix (ASX:DXB) Fell 35% Today; Not About The Data, But About the Timing Stocks Down Under
Dimerix Releases Investor Presentation and Video Recording
other announcement
Dimerix to conduct blinded review of phase III kidney disease trial data
Dimerix to conduct blinded review of ACTION3 data later this month to confirm statistical assumptions for primary endpoint ... Read More The post Dimerix to conduct blinded review of phase III kidney disease trial data appeared first on Stockhead.
Dimerix Presents at Euroz Hartleys Institutional Conference
other announcement
Dimerix to Conduct Review of ACTION3 Statistical Assumptions
other announcement
Dimerix doses final patient in Phase III kidney disease trial as enrolment exceeds target
Dimerix’s ACTION3 study DMX-200 in focal segmental glomerulosclerosis doses final adult patient with 333 patients recruited ... Read More The post Dimerix doses final patient in Phase III kidney disease trial as enrolment exceeds target appeared first on Stockhead.
Dimerix Phase 3 Trial Last Patient Receives First Dose
other announcement
Dimerix Invitation to Perth and Singapore Investor Briefings
other announcement
Dimerix Presents at Oppenheimer Life Sciences Conference
other announcement
Dimerix to Present at Euroz Hartleys Healthcare Forum 2026
other announcement
Clinical trial update at J.P. Morgan Healthcare Conference
other announcement
Dimerix receives input from FDA on ACTION3 trial endpoints
other announcement
BioMarin to acquire Dimerix US Partner, Amicus Therapeutics
other announcement
DMX-200 ACTION3 Phase 3 Trial Completes Recruitment
other announcement
Change of Director's Interest Notice - CS,HA,NW,SP & MD
director_dealing announcement
Canaccord Drug & Device Conference Investor Presentation
other announcement
2025 AGM Notice of Meeting, Letter of Access and Proxy
other announcement
Successful PARASOL Collaboration Data Analysis Outcome
other announcement
Change of Director's Interest Notice - SP
director_dealing announcement
Dimerix receives 1st Development Milestone payment from FUSO
other announcement
Change of Director's Interest Notice - SP
director_dealing announcement
ACTION3 Clinical Trial Milestone Recruitment Update
other announcement